Brain Metastases from Endometrial Carcinoma by Piura, Ettie & Piura, Benjamin
International Scholarly Research Network
ISRN Oncology
Volume 2012, Article ID 581749, 13 pages
doi:10.5402/2012/581749
Review Article
Brain Metastases from Endometrial Carcinoma
Ettie Piura1 andBenjamin Piura2
1Department of Obstetrics and Gynecology, Sapir Medical Center, Sackler School of Medicine, University of Tel-Aviv,
Kfar Saba 44281, Israel
2Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences,
Ben-Gurion University of the Negev, Beer Sheva 84101, Israel
Correspondence should be addressed to Benjamin Piura, piura@bgu.ac.il
Received 16 December 2011; Accepted 7 January 2012
Academic Editors: A. Abdollahi and M. Amichetti
Copyright © 2012 E. Piura and B. Piura. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
This paper will focus on knowledge related to brain metastases from endometrial carcinoma. To date, 115 cases were documented
in the literature with an incidence of 0.6% among endometrial carcinoma patients. The endometrial carcinoma was usually an
advanced-stage and high-grade tumor. In most patients (∼90%), brain metastasis was detected after diagnosis of endometrial
carcinoma with a median interval from diagnosis of endometrial carcinoma to diagnosis of brain metastases of 17 months. Brain
metastasis from endometrial carcinoma was either an isolated disease limited to the brain only (∼50%) or part of a disseminated
disease involving also other parts of the body (∼50%). Most often, brain metastasis from endometrial carcinoma aﬀected the
cerebrum (∼75%) and was solitary (∼60%). The median survival after diagnosis of brain metastases from endometrial carcinoma
was 5 months; however, a signiﬁcantly better survival was achieved with multimodal therapy including surgical resection or
stereotactic radiosurgery followed by whole brain radiotherapy (WBRT) and/or chemotherapy compared to WBRT alone. It is
suggested that brain imaging studies should be considered in the routine follow up of patients with endometrial carcinoma and
that the search for a primary source in females with brain metastases of unknown primary should include endometrial biopsy.
1.Introduction
The brain, along with the bone, liver, and lung, is one of
the most common sites of metastases with about 170,000
patients newly diagnosed with brain metastases each year in
USA, a ﬁgure which is 10-fold higher than that of patients
newly diagnosed with primary brain malignancy [1–3].
Common sources of brain metastases are lung, breast, renal,
and colorectal carcinoma and malignant melanoma; it has
been estimated that about 15% of patients with these cancers
develop brain metastases in the course of their disease [1, 3–
5]. Female genital tract cancers, however, are considered
“neurophobic” since brain metastases from female genital
tract cancers, apart from choriocarcinoma, are rare and
usually develop as part of a widespread disseminated disease.
The primary mechanism of metastatic spread from genital
tract cancers to the brain is by the hematogenous rout.
Detached tumor cells are carried from the genital tract by the
blood stream through the inferior vena cava, right atrium,
right ventricle, pulmonary artery, lungs, pulmonary veins,
left atrium, left ventricle, and aorta to the brain [6]. It has
been speculated that tumor cells from the genital tract may
also travel to the brain via the Batson plexus (paravertebral
venous plexus) [3]. Ogawa et al. [6] surveyed 2,729 women
with primary genital tract cancers treated during 1985–2006
and identiﬁed 18 women (0.7%) with brain metastases.
The incidence of brain metastases from ovarian carcinoma
(7/335, 2.1%) was higher than those from endometrial
carcinoma (4/556, 0.7%), uterine cervix carcinoma (7/1716,
0.4%),andotherfemalegenitaltractmalignanciescombined
(vagina, vulva, and fallopian tube carcinoma) (0/122, 0%)
[6].
In USA, the number of women newly diagnosed with
endometrial carcinoma and the number of women dead of
endometrial carcinoma in 2010 has been estimated to be
43,470 and 7,950, respectively [7]. The age-adjusted inci-
dence (number of new cases per 100,000 women per year)
and age-adjusted death rate (number of deaths per 100,000
women per year) in 2007 was 24.74 and 4.18, respectively
[8].EndometrialcarcinomainUSAistheﬁrstmostcommon2 ISRN Oncology
cancer of the female genital tract, the fourth most common
malignancy (after breast, lung, and colorectal cancer) in
females accounting for 6% of all cancers in females [7, 8]. It
is the eighth most common cause of death from cancer (after
lung, breast, colorectal, pancreatic, and ovarian cancer, non-
Hodgkin’s lymphoma, and leukemia) in females accounting
for 3% of all deaths from cancer in females [7]. The National
Cancer Institute (NCI) has estimated that the lifetime risk of
being diagnosed with endometrial carcinoma and of dying
from endometrial carcinoma in females born today in USA
is 2.6% (1/38) and 0.5% (1/200), respectively [8].
In the European Union countries combined (EU-27), the
age-standardized incidence of endometrial carcinoma and
age-standardized death rate from endometrial carcinoma in
2007 was 16.2 and 3, respectively [9]. In UK, the number
of women newly diagnosed with endometrial carcinoma
in 2007 was 7,536, and the number of women dead of
endometrial carcinoma in 2008 was 1,741 [9]. The age-
standardized incidence and death rate in 2008 was 15.7 and
3.1,respectively[9].EndometrialcarcinomainUKistheﬁrst
most common cancer of the female genital tract, the fourth
most common cancer in women accounting for 5% of all
cancers in females [9, 10].
Worldwide, endometrial carcinoma is the sixth most
commoncancer(afterbreast,colorectal,uterine cervix,lung,
and gastric cancer) in women with an estimated 287,100 new
cases diagnosed in 2008 (4.8% of all cancers in women) and
anincidenceof8.2[11,12].Endometrialcarcinomahasbeen
estimated to cause 74,000 deaths in 2008 worldwide (2.2% of
allcancerdeathsinwomen)withanestimateddeathrateof2
[11]. In 2008, the incidence and death rate from endometrial
carcinoma was 12.9 and 2.4, respectively, in more developed
countries and 5.9 and 1.7, respectively, in less developed
countries [12]. Thus, endometrial carcinoma is primarily a
cancer of the developed world with incidence rates double
thoseofthelessdevelopedcountries.Endometrialcarcinoma
incidence rates are highest in Northern America, up to eight
times higher than in parts of Africa [9, 12].
The vast majority (>90%) of endometrial carcinomas
are diagnosed in women aged over 50 years with very few
women diagnosed under the age of 35. Incidence after
the menopause rises rapidly to a peak of 82 in women
in their early seventies [9]. Most (∼75%) patients with
endometrial carcinoma are diagnosed with an early-stage
disease (F.I.G.O. Stage I and II) and the rest (∼25%) with
an advanced-stage disease (F.I.G.O. Stage III and IV). After
primarytherapyincludingtotalabdominalhysterectomyand
bilateral salpingo-oophorectomy followed, if necessary, by
adjuvant pelvic radiotherapy, most patients with an early-
stage disease will enjoy an overall good prognosis with
a 5-year survival rate of about 90%. Nevertheless, even
in patients with early-stage disease, survival is lower, and
recurrenceismorelikelywithcertainadversefeaturessuchas
high-grade tumors, deep myometrial invasion, unfavorable
histologic types, and extension to the uterine cervix [13].
Patients with advanced-stage endometrial carcinoma have
a poor prognosis with a median survival often less than
one year [13]. The NCI has estimated that endometrial
carcinoma at initial diagnosis is found to be localized in the
uterus in 70% of the patients (5-year survival rate, 95.5%),
with loco-regional extension in 20% of the patients (5-year
survival rate, 67.5%) and with distant metastases in 10% of
the patients (5-year survival rate, 17.1%) [8]. Although the
majority of endometrial carcinoma patients are diagnosed at
anearlystagewithanexcellentlong-termprognosis,10–30%
of patients develop a recurrent disease [14–16]. Noteworthy,
although mortality from endometrial carcinoma declined
during the last decades of the twentieth century, there have
been reports that endometrial carcinoma incidence and
mortality rates are rising in UK and USA [10, 17, 18]. This
increase may be attributable to the increase in body mass
index in women, but other causes are possible [10].
Endometrial carcinoma usually spreads by lymphatic
vessels to pelvic and para-aortic lymph nodes and by
local invasion to the ovaries and surrounding tissues.
Less frequently, endometrial carcinoma spreads through
the hematogenous pathway. The most frequent sites of
hematogenous metastases of endometrial carcinoma are the
lungs, including the pleura and mediastinum, liver, and
bone[19–21].Therehavebeenseveralhypothesesexplaining
the site of preference of distant metastasis from various
cancers. Paget [22] proposed in 1889 his “seed and soil”
hypothesis, which suggested that speciﬁc tumor cell prop-
erties and diﬀerences in the microenvironment in various
organs are responsible for the nonrandom distribution of
metastases. Nicolson and Winkelhake [23]s u g g e s t e di n
1975 the possibility that speciﬁc cell surface properties of
metastasizing tumor cells, and particular properties of the
vascular endothelium of the target organs are responsible for
the location of distant metastases. This may explain clinical
and experimental evidence indicating that circulating tumor
cells are present in a wide variety of organs, but implantation
of tumor cells occurs only in certain tissues.
Aalders et al. [24] observed that 379 (11.2%) of 3,393
endometrial carcinoma patients referred to the Norwegian
Radium Hospital during 1960–1976 developed recurrent
disease. Of the 379 patients with recurrent endometrial
carcinoma, 190 (50.1%) had local recurrence, 108 (28.5%)
had distant metastases, and 81 (21.4%) had both local
recurrence and distant metastases. Sites of distant metastases
were the lung: 63 patients, upper abdomen: 48, multiple
sites: 26, bone: 22, brain: 11, liver: 10, and lymph nodes:
9. Within one year after completion of primary therapy
for endometrial carcinoma, 35% of the local recurrences
and 25% of the distant metastases were apparent. Within 3
years, 75% of the local recurrences and 72% of the distant
metastases were evident. In about 10% of the patients,
however, the recurrence appeared more than 5 years after
primary therapy [24]. Sohaib et al. [16] reviewed 86 patients
with recurrent endometrial carcinoma following primary
surgery and found that disease relapse was detected at an
overall median time of 13 months (range, 1–108 months)
after primary surgery. Sixty-four percent of relapses were
detected within 2 years of surgery, 87% had occurred within
3 years, and 97% within 5 years. The disease recurred locally
in 30 (35%) patients (median time to relapse, 11.5 months),
distally in 32 (37%) patients (median time to relapse, 20.5
months) and locally and distally in 24 (28%) patientsISRN Oncology 3
(median time to relapse, 8.5 months). Sites of recurrence
were lymph nodes in 41 (48%) patients, vagina: 36 (42%),
peritoneum: 23 (27%), lung: 21 (24%), hydronephrosis:
20 (23%), bladder: 7 (8%), liver: 6 (7%), bone: 6 (7%),
abdominal wall: 6 (7%), spleen: 4 (5%), rectum: 3 (3%),
pancreas: 1 (1%), muscle: 1 (1%), and brain: 1 (1%) (the
number of sites of recurrence sums up to more than 86
because a quantity of patients had more than one site of
recurrence) [16].
Brain metastasis from endometrial carcinoma is rare
with only 115 patients documented in the literature [16,
19, 21, 24–55]( Table 1). Of 35 papers on brain metastases
from endometrial carcinoma published in the literature,
19 documented one patient each [16, 19, 21, 25–29, 32,
38, 40, 43–45, 48, 49, 52, 54, 55], seven: 2 patients each
[33–35, 37, 39, 42, 47], two: 3 patients each [30, 50],
one: 6 patients [53], one: 8 patients [46], two: 10 patients
each [36, 41], two: 11 patients [24, 31], and one: 20
patients [51]. Age at diagnosis of brain metastases from
endometrial carcinoma ranged from 40 to 83 years with
a median of 60 years (Table 1). Because of the rarity of
brain metastases from endometrial carcinoma, the accrual
of patients occurred over prolonged periods of time during
which treatment approaches and modalities changed. This
paper will focus on the following topics related to brain
metastases from endometrial carcinoma: characteristics of
the primary endometrial carcinoma, brain metastases from
endometrial carcinoma in autopsy series, incidence of brain
metastases from endometrial carcinoma, interval between
diagnosis of endometrial carcinoma and brain metastases,
type and site of brain metastases, symptoms and signs of
brain metastases, treatment of brain metastases, and survival
after diagnosis of brain metastases.
2.Characteristicsof the Primary
Endometrial Carcinoma
ThedistributionoftheF.I.G.O.Stageatdiagnosisofendome-
trial carcinoma in the patients with brain metastases from
endometrial carcinoma collated from 35 papers published
in the literature [16, 19, 21, 24–55] was as follows: Stage
0 (endometrial intraepithelial neoplasm, EIN): 1 patient,
I( n o ts u b s t a g e d ) :4 ,I a :4 ,I b :7 ,I c :4( S t a g eIo v e r a l l :
19), IIa: 2, IIb: 7 (Stage II overall: 9), IIIa: 11, IIIb: 3,
IIIc: 18 (Stage III overall: 32), IV (not substaged): 6, IVa:
1, IVb: 11 (Stage IV overall: 18), and not available: 26
(Table 1). Of the 79 patients in whom stage of endometrial
carcinoma at initial diagnosis was known, 29 (36.7%) had
Stage I + II, and 50 (63.3%) had Stage III + IV. Grade of
endometrial carcinoma was G1 in 4 patients, G2: 12, G3:
27, and unknown: 32 (Table 1). Of the 73 patients in whom
grade of endometrial carcinoma was known, 4 (5.5%) had
G1, 12 (16.4%): G2, and 57 (78.1%): G3. Histological type of
endometrial carcinoma was adenocarcinoma in 63 patients,
adenosquamous carcinoma: 10, clear cell carcinoma: 4,
serous carcinoma: 4, carcinosarcoma: 3, undiﬀerentiated: 3,
and unknown: 18 (Table 1). Of the 87 patients in whom
histological type of endometrial carcinoma was known,
63 (72.4%) had adenocarcinoma and 24 (27.6%) had
other types of endometrial carcinoma (“unfavorable types”).
Cormio et al. [36] observed that compared to all patients
registered for endometrial carcinoma at their institution
(1,069 patients) during 1982–1994, those who developed
brain metastases (10 patients) had at the time of diagnosis
of the primary tumor a higher percentage of advanced-stage
disease (50% versus 16%) and higher percentage of poorly-
diﬀerentiated tumors (60% versus 23%). Of 10 patients with
brain metastases from endometrial carcinoma reported by
Mahmoud-Ahmed et al. [41], 9 (90%) had at the time of
diagnosis of the primary tumor an advanced-stage disease
(Stage III or IV). At the time of diagnosis of the primary
endometrial carcinoma in 8 patients with brain metastases
reported by Gien at al. [46], 6 (75%) presented with an
advanced-stage (Stage III or IV) disease and 5 (62.5%)
with a poorly-diﬀerentiated (G3) tumor. All 3 patients with
brain metastases from endometrial carcinoma documented
by Orr` u et al. [50] had at the time of diagnosis of the
primary disease a poorly-diﬀerentiated (G3) advanced-stage
(Stage III) endometrial carcinoma. At the time of diagnosis
of the primary endometrial carcinoma in 20 patients with
brain metastases reported by Chura et al. [51], 17 (85%)
presented with an advanced-stage (Stage III or IV) disease,
11 (55%) with a poorly-diﬀerentiated (G3) tumor, and 8
(40%) with an unfavorable histologic type (carcinosarcoma,
adenosquamous carcinoma, and serous carcinoma).
Primary therapy for endometrial carcinoma was total
abdominal hysterectomy and bilateral salpingo-oophorecto-
myin43patients,totalabdominalhysterectomyandbilateral
salpingo-oophorectomy and lymphadenectomy: 33, pelvic
radiotherapy and chemotherapy: 5, pelvic radiotherapy: 1,
no therapy: 5, and unknown: 18 (Table 1). Of the 87 patients
in whom primary therapy of the endometrial carcinoma was
known, 76 (87.4%) had surgery with at least total abdominal
hysterectomy and bilateral salpingo-oophorectomy, 6 (6.9%)
had radiotherapy, and 5 (5.7%) had no therapy. In the
76 patients who had primary surgery for the endometrial
carcinoma, postoperative adjuvant therapy was pelvic radio-
therapy in 42 (55.3%) patients, pelvic radiotherapy, and
chemotherapy:10(13.2%),chemotherapy:16(21%),andno
or unknown adjuvant therapy: 8 (10.5%) (Table 1).
It can be concluded that in most patients who develop
brain metastases from endometrial carcinoma, the endome-
trial carcinoma at the time of diagnosis was an advanced-
stage (III/IV) (two-thirds of the patients) and high-grade
(G3) (80% of the patients) disease that relapsed despite
primary therapy with surgery including total abdominal
hysterectomy and bilateral salpingo-oophorectomy followed
by adjuvant pelvic radiotherapy.
3.BrainMetastasesfromEndometrial
Carcinoma in Autopsy Series
3.1. Autopsy of Endometrial Carcinoma Patients. Henriksen
[20] surveyed 188 necropsies of endometrial carcinoma
patients and revealed 2 (1%) patients with brain metastasis.
Berge and Lundberg [56] studied postmortem examinations
of 111 patients with endometrial carcinoma and revealed
that 40 patients had metastasizing disease; however, no brain4 ISRN Oncology
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metastases were found, but there was one metastases in the
meninges.
3.2. Autopsy of Patients with Brain Metastases. In a Japanese
series of 101 postmortem examinations performed on
patients with surgically treated metastatic brain tumors,
there was one case of endometrial carcinoma as opposed to
59 cases of lung carcinoma and 4 cases of cervical carcinoma
[57].
3.3. Autopsy of Patients in General. In 15,000 autopsies
reviewed retrospectively at the department of pathology,
Innsbruck University Hospital, Innsbruck, Austria, there was
one case of endometrial carcinoma with brain metastases
[58].
4. Incidenceof BrainMetastasesfrom
Endometrial Carcinoma
4.1. Incidence of Brain Metastases among Endometrial Car-
cinoma Patients (Table 1). Aalders et al. [24] found 11
patients with brain metastases from endometrial carci-
noma managed at the Norwegian Radium Hospital, Oslo,
Norway between 1960 and 1976, accounting for 0.3% of
3,393 patients with endometrial carcinoma and 2.9% of
379 patients with recurrent endometrial carcinoma. De
Porre and Tjokrowardojo [31] reviewed 2,293 patients with
endometrial carcinoma treated at the Dr. Daniel den Hoed
Cancer Center, Rotterdam, The Netherlands during 1965–
1988 and found 11 (0.48%) patients with brain metastases.
Cormio et al. [36] found 10 (0.9%) patients with brain
metastases among 1,069 endometrial carcinoma patients
treated at the Ospedale S. Gerardo, Monza, Italy during
1982–1994. The risk of developing brain metastases was
quite low for both patients with advanced-stage endometrial
carcinoma (2/64, 3%) and recurrent endometrial carcinoma
(8/143,6%).However,brainmetastasiswasseenin8(29.6%)
of 27 patients with distant recurrent disease [36]. Gien et
al. [46] reviewed 1,295 patients with endometrial carcinoma
referred to the London Regional Cancer Centre University
of Western Ontario, Canada during 1991–2003 and found
that 8 (0.6%) of these women developed brain metastases.
Sohaib et al. [16] reviewed 86 patients with recurrent
endometrial carcinoma following primary surgery managed
at the Royal Marsden Hospital, London, UK during 1996–
2004 and found one patient (1.16%) with brain metastases.
Chura et al. [51] found 20 (0.97%) patients with brain
metastases among 2,063 endometrial carcinoma patients
treated at the University of Minnesota, Women’s Cancer
Center, Minneapolis, USA during 1995–2006. In six reports
in which the number of endometrial carcinoma patients
is available, 10,199 endometrial carcinoma patients were
surveyed overall and 61 (0.59%) of them were found to have
brain metastases [16, 24, 31, 36, 46, 51].
4.2.IncidenceofEndometrialCarcinomaastheSourceofBrain
Metastases among Patients with Brain Metastases (Table 1).
Mahmoud Ahmed et al. [41] revealed that endometrial
carcinoma was the source of brain metastases in 10 (0.7%)
of 1,391 patients with brain metastases treated in their
institution during 1982–1999. Orr` u et al. [50] found that
endometrial carcinoma was the source of brain metastases
in 3 (0.9%) of 348 patients with brain metastases referred
to the Businco Regional Oncological Hospital, Cagliari, Italy
for palliative radiotherapy during 1999–2005. Le Chevalier
et al. [59] reviewed retrospectively 120 consecutive patients
presenting to The Gustave-Roussy Institute, Villejuif, France
during 1959–1979 with brain metastases as the ﬁrst sign of
their malignancy. The primary malignancy was identiﬁed in
62 patients (53 alive and 6 dead of disease); endometrial
carcinoma was the source of brain metastases in one (1.6%)
patient [59]. Overall, thus, endometrial carcinoma was the
sourceofbrainmetastasesin14(0.7%)of1,801patientswith
brain metastases.
5. IntervalbetweenDiagnosisof Endometrial
CarcinomaandBrain Metastasis
The interval between diagnosis of endometrial carcinoma
and brain metastasis was available in 95 of 115 patients
withbrainmetastasesdocumentedintheliterature(Table 1).
In 82 (86.3%) of these 95 patients, brain metastasis was
detected after diagnosis of endometrial carcinoma with an
interval between diagnosis of endometrial carcinoma and
brain metastasis ranging from 2 to 108 months (median, 17
months). In 4 (4.2%) of the 95 patients, brain metastasis was
diagnosed simultaneously with endometrial carcinoma [28,
30, 44, 49]. In 9 (9.5%) of the 95 patients, brain metastasis
was detected before the diagnosis of endometrial carcinoma;
in 4 patients brain metastasis was detected 0.25 [34], 0.5
[47], 2.5 [30], and 3 months [30], respectively, before the
diagnosisofendometrialcarcinomaandin5patients[35,41,
42] brain metastasis was detected at unknown time before
the diagnosis of endometrial carcinoma. Thus, although in
the vast majority of patients (∼90%) brain metastasis from
endometrial carcinoma is detected late in the course of the
primary disease, in some patients (∼10%) brain metastasis
is detected simultaneously with the primary disease and
sometimes even before the detection of the primary disease.
Kottke-Marchant et al. [30] showed that invasive, high-
grade endometrial carcinoma with vascular invasion may
metastasize very early in the course of disease, even before
clinical symptoms related to the primary tumor become
apparent.Therefore,ithasbeenrecommendedthatthestudy
of brain metastasis of unknown primary site should include
endometrial biopsy [38].
6.TypeandSiteof BrainMetastasis
Type of brain metastasis with respect to whether the
metastasis is conﬁned to the brain only (isolated brain
metastasis) or is part of a disseminated disease was available
for 98 patients (Table 1). Of these 98 patients, 48 (49%)
had metastasis conﬁned to the brain only, and 50 (51%)
had brain metastasis as part of a disseminated disease
that aﬀects also extracranial sites. Among patients with
concomitant extracranial metastatic disease at diagnosis of
brain metastasis, the most common sites of extracranial8 ISRN Oncology
recurrence were the pelvis, peritoneum, lung, bone, liver,
and lymph nodes [36, 41, 46, 51]. Interestingly, half of the
patients with brain metastasis from endometrial carcinoma
documented in the literature had metastasis conﬁned to the
brain only (isolated brain metastasis). Of 10 patients with
brain metastases from endometrial carcinoma reported by
Cormio et al. [36], 6 (60%) had isolated brain metastases
(no other sites of disease) and survived after diagnosis of
brain metastases for a median of 3 months (range, 1–83
months) whereas 4 (40%) had brain metastases as part of a
disseminated disease and survived for a median of 1 month
(range, 1-2 months). Of 10 patients with brain metastases
from endometrial carcinoma reported by Mahmoud-Ahmed
[41], 3 (30%) had isolated brain metastases and survived
after diagnosis of brain metastases for a median of 6
months(range,1.5–11.5months)whereas7(70%)hadbrain
metastases as part of a disseminated disease and survived
for a median of 2.5 months (range, 0.25–15 months). Of 8
patients with brain metastases from endometrial carcinoma
reported by Gien et al. [46], 2 (25%) had isolated brain
metastases and survived after diagnosis of brain metastases
for a median of 4.5 months (range, 2–7 months) whereas
6 (75%) had brain metastases as part of a disseminated
disease and survived for a median of 3.5 months (range,
0.25–7 months). Of 20 patients with brain metastases from
endometrial carcinoma reported by Chura et al. [51], 4
(20%) had isolated brain metastases and survived after
diagnosis of brain metastases for a median of 31.5 months
(range, 9.2–39.2 months) whereas 16 (80%) had brain
metastases as part of a disseminated disease and survived for
a median of 1.1 months (range, 0.1–10.9 months).
Amount of brain metastases with respect to whether the
metastasis is single (solitary) brain metastases or multiple
brain metastases was available for 88 patients (Table 1). Of
these 88 patients, 50 (56.8%) patients had single (solitary)
brain metastases, and 38 (43.2%) patients had multiple
brain metastases. Of 10 patients with brain metastases from
endometrial carcinoma reported by Cormio et al. [36],
6 (60%) had single brain metastases and survived after
diagnosis of brain metastases for a median of 2.5 months
(range, 1–83 months) whereas 4 (40%) had multiple brain
metastases and survived for a median of 1 month (range,
1–3 months). Of 10 patients with brain metastases from
endometrial carcinoma reported by Mahmoud-Ahmed [41],
3 (30%) had single brain metastases and survived after
diagnosis of brain metastases for a median of 15 months
(range, 11.5–15.5 months) whereas 7 (70%) had multiple
brain metastases and survived for a median of 2.5 months
(range, 0.25–6 months). Of 8 patients with brain metastases
from endometrial carcinoma reported by Gien et al. [46],
4 (50%) had single brain metastases and survived after
diagnosis of brain metastases for a median of 3 months
(range, 0.5–7 months) whereas 4 (50%) had multiple brain
metastases and survived for a median of 3.5 months (range,
0.25–7 months). Of 20 patients with brain metastases from
endometrial carcinoma reported by Chura et al. [51], 8
(40%) had single brain metastases, 4 (20%) had 2 brain
metastases,7(35%)had≥3brainmetastases,and1(5%)had
leptomeningeal disease. There was no signiﬁcant diﬀerence
in survival between patients with 1 or 2 brain metastases
(median survival, 3.1 months) and patients with ≥3b r a i n
metastases (median survival, 2.1 months) (P = 0.58) [51].
Site of metastasis in the brain with respect to whether
the metastasis is supratentorial (cerebrum) or infratentorial
(cerebellum) or both was available for 66 patients (Table 1).
Of these 66 patients, 48 (72.7%) patients had supratentorial
metastasis, 10 (15.2%) patients had infratentorial metastasis,
and 8 (12.1%) patients had both supratentorial and infraten-
torial metastasis. This is in contrast to Delattre et al. [60]
who observed in 1988 that substantial fraction (50%) of
solitary (single) brain metastases from primary pelvic and
abdominaltumorsislocatedinfratentorially(posteriorfossa,
cerebellum). The relatively higher frequency of infratentorial
metastasis from primary pelvic and abdominal tumors com-
pared to other primary tumors was explained by the role of
Batson’s paravertebral venous plexus [60]. Nevertheless, the
role of Batson’s paravertebral plexus in directing metastatic
tumorcellsfromthepelvisandabdomentotheinfratentorial
region of the brain is dubious since there is no concomitant
higher frequency of spine and skull metastases from primary
pelvic and abdominal tumors compared to other primary
tumors [38]. Of 10 patients with brain metastases from
endometrial carcinoma reported by Cormio et al. [36], 7
(70%) had metastases located in the cerebrum and survived
after diagnosis of brain metastases for a median of 3 months
(range, 1–83 months), 1 (10%) had metastases located in
the cerebellum (survival, 3 months), and 2 (20%) had
metastases located in both the cerebrum and cerebellum
(survival, 1 month). Of 10 patients with brain metastases
from endometrial carcinoma reported by Mahmoud-Ahmed
[41], 8 (80%) had metastases located in the cerebrum and
survived after diagnosis of brain metastases for a median
of 2.4 months (range, 0.25–15.5 months), 1 (10%) had
metastases located in the cerebellum (survival, 15 months),
and 1 (10%) had metastases located in both the cerebrum
andcerebellum(survival,6months).Of8patientswithbrain
metastases from endometrial carcinoma reported by Gien et
al. [46], 4 (50%) had metastases located in the cerebrum and
survived after diagnosis of brain metastases for a median of
1.25 month (range, 0.25–7 months), 2 (25%) had metastases
l o c a t e di nt h ec e r e b e l l u ma n ds u r v i v e df o ram e d i a no f3
months (range, 1–5 months), and 2 (25%) had metastases
located in both the cerebrum and cerebellum and survived
for a median of 6 months (5–7 months).
Thus, it can be concluded that brain metastasis
from endometrial carcinoma is situated in the cerebral
parenchyma in almost 75% of the patients and is solitary
(single brain metastases) in almost 60% of the patients.
Brain metastasis from endometrial carcinoma is an isolated
metastatic disease conﬁned to the brain alone in half of the
patients and part of a disseminated disease that aﬀects also
extracranial sites in the other half of the patients.
7.Symptoms andSigns of BrainMetastases
from Endometrial Carcinoma
Symptoms and signs of brain metastases from endometrial
carcinoma are not diﬀerent from symptoms and signs ofISRN Oncology 9
other brain space occupying lesions. In a series of 10
patients with brain metastases from endometrial carcinoma
reported by Cormio et al. [36], headache was present in 8
patients, motor weakness: 5, seizures: 2, confusion, dizziness,
balance, and visual disturbances: 1 patient each. In 10
patients with brain metastases from endometrial carcinoma
reported by Mahmoud-Ahmed [41], loss of consciousness,
seizures, motor weakness, and headache were the most
common symptoms. All 10 patients reported by Gien et
al. [46] developed neurological symptoms, primarily motor
dysfunction, speech diﬃculty, and mental confusion. In 3
patients reported by Orr` u et al. [50], aphasia developed in
2 patients, memory loss: 1, hemiparesis: 1, and headache:
1, and temporary loss of consciousness: 1. In a series
of 20 patients with brain metastases from endometrial
carcinoma reported by Chura et al. [51], the most common
neurologic symptoms were confusion: 9 (45%) patients, gait
disturbance: 8 (40%), paralysis: 4 (20%), speech diﬃculty:
2 (10%), and nausea and vomiting: 2 (10%). In the singular
casereportsofbrainmetastasesfromendometrialcarcinoma
published in the literature, common presenting symptoms
and signs of brain metastases included headache, confusion,
dizziness, decreased mental status, consciousness distur-
bance, general weakness, extremity weakness, gait distur-
bance, neurological motor deﬁcit, hemiparesis, ataxia, visual
disturbance, papilledema, incontinence, nausea, vomiting,
speech impairment (aphasis), parasthesias, syncope, and
seizure.
In the vast majority of cases, it was the emergence of one
of more neurological symptoms and signs in endometrial
carcinoma patients that provoked a search for brain metas-
tases with use of brain-imaging studies, most often brain-
computed tomography (CT) and less often magnetic reso-
nance imaging (MRI) or both CT and MRI. In many cases,
the lesions demonstrated on CT and MRI were associated
with brain edema [36]. The brain edema due to the growth
of metastases in the brain parenchyma causes increased
intracranial pressure which is the main reason for the
headache, nausea, vomiting, and papilledema. In the largest
series of patients with brain metastases from endometrial
carcinoma published in the literature (20 patients), Chura et
al. [51] showed that the diagnosis of brain metastases was
established with both CT and MRI in 8 (40%) patients, MRI
alone in 8 (40%) patients, and CT alone in 4 (20%) patients.
8. Treatment of BrainMetastasesfrom
Endometrial Carcinoma
Data with respect to treatment modality of brain metastases
was available for 91 patients (Table 1). Of these 91 patients,
10 (11%) patients had surgery (craniotomy, resection of
brain metastases) alone, 21 (23.1%): surgery followed by
whole-brain radiotherapy (WBRT), 7 (7.7%): surgery fol-
lowed by WBRT and chemotherapy, 1 (1.1%): surgery fol-
lowed by stereotactic radiosurgery (SRS) and chemotherapy,
8 (8.8%): SRS alone, 26 (28.5%): WBRT alone, 1 (1.1%):
WBRTfollowedbySRS,5(5.5%):chemotherapyandWBRT,
1 (1.1%): oral poly(ADP)-ribose polymerase (PARP) 1
inhibitor (Olaparib) alone, 7 (7.7%): steroids alone, and 4
(4.4%): no treatment. Thus, overall, 60 (65.9%) patients had
WBRT, 39 (42.8%): craniotomy, 13 (14.3%): chemotherapy,
and 10 (11%): SRS (number of patients adds up to more
than 91 since some patients had more than one treatment
modality). Craniotomy usually consisted of gross total
resection of the brain metastases and sometimes of subtotal
resection of the brain metastases. As a rule, WBRT consisted
of external megavoltage photonic irradiation employing a
10MeV linear accelerator delivering a total dose of 30 Gray
(3,000RAD) to the whole brain in daily fractions (3 Gray per
fraction for 10 fractions).
In the series of 10 patients with brain metastases from
endometrial carcinoma reported by Cormio et al. [36], brain
metastasis was treated by craniotomy alone in 1 patient
(developed lung metastases after 2 months for which she
received cisplatin-based chemotherapy and still alive at last
followup), craniotomy followed by WBRT in 2 patients (died
after 28 and 83 months, resp.), WBRT alone in 1 patient
(died after 3 months) and steroids alone in 6 patients (all
died within 1 month of diagnosis). Of note, in 7 of the
9 patients who died, the cause of death was attributed to
progressive brain metastasis [36]. The authors conclude that
surgical resection of the brain metastases followed by WBRT
is considered the best option in patients with solitary and/or
resectable metastases in presence of control of systemic
disease.
In the series of 10 patients with brain metastases from
endometrial carcinoma reported by Mahmoud-Ahmed et
al. [41], brain metastasis was treated by WBRT in 5 (50%)
patients (one of them had SRS + WBRT), craniotomy alone
in 2 (20%) patients, and craniotomy followed by WBRT in 3
(30%) patients (in one of them craniotomy was followed by
S R S+W B R T ) .T h u s ,o v e r a l l ,W B R Tw a sg i v e nt o8( 8 0 % )
patients, SRS was used in 2 (20%) patients, and craniotomy
was performed in 5 (50%) patients (number of patients adds
up to more than 10 since some patients had more than
one treatment modality). The authors [41] observed that
the 3 patients who had multimodal therapy with craniotomy
followed by WBRT ± SRS had a longer survival (median, 15
months; range, 11.5–15.5 months) than the 5 patients who
had WBRT without craniotomy (median. 2.4 months; range,
0.25–6 months) and the 2 patients who had craniotomy
alone (median, 2.75 months; range, 1.5–4 months).
Chura et al. [51] reviewed 20 patients with brain metas-
tases from endometrial carcinoma treated at the University
of Minnesota, Women’s Cancer Center, Minneapolis, USA
during 1995–2006 and found that 7 (35%) patients had
WBRT alone, 4 (20%): WBRT followed by chemotherapy
(cisplatin and doxorubicin: 2 patients, carboplatin: 1 patient,
thalidomide: 1 patient), 1 (5%): craniotomy followed by
WBRT, 1 (5%): WBRT followed by SRS, 3 (15%): WBRT,
craniotomy and chemotherapy (cisplatin and doxorubicin: 2
patients), topotecan: 1 patient), and 4 (20%): no treatment.
Thus, overall, WBRT was the cornerstone of treatment for all
16 (80%) patients who had therapy for brain metastases, and
chemotherapy was given to 7 (35%) patients, craniotomy
was performed in 4 (20%) patients, SRS was performed in
1 (5%) patient, and no treatment was given to 4 (20%)
patients (the number of patients adds up to more than 2010 ISRN Oncology
since some patients had more than one treatment modality).
The authors [51] showed that multimodal therapy of brain
metastases (WBRT + craniotomy, WBRT + craniotomy +
chemotherapy, WBRT + chemotherapy) resulted in a longer
survival (median, 9.2 months) compared to WBRT alone
(median, 0.9 months) (P = 0.0001) or no treatment
(median, 0.2 months) (P = 0.009).
In studies of brain metastasis from endometrial carci-
noma published in the literature, patient accrual occurred
over prolonged periods of time during which treatment
approaches and modalities for brain metastases changed.
Traditionally, patients with isolated (limited to the brain
only) and single (solitary) brain metastases generally would
undergo resection of the brain metastases by craniotomy
followed by WBRT. Patients with multiple brain metastases
(with or without extracranial disease) generally would
receive WBRT alone. In series and singular case reports
published in literature before 2001, stereotactic radiosurgery
(SRS) or gamma-knife radiosurgery (GKRS) was yet not
included in the treatment of brain metastases from endome-
trial carcinoma. Petru et al. [42] described in 2001 two
patients in whom brain metastases were detected prior to
diagnosis of primary endometrial carcinoma. The brain
metastases in both patients were treated by SRS. One of
these patients died of disease 15 months after diagnosis of
brain metastases. The other patient was still alive at the
time of writing the report; with no evidence of disease, 171
months after she had SRS for a solitary (single) brain metas-
tases and aggressive cytoreductive abdominal and pelvic
surgeryfollowedbydoxorubicin-basedchemotherapyforthe
endometrial carcinoma [42]. Shiohara et al. [44]r e p o r t e di n
2003 a woman who underwent the removal of a single brain
metastasesandonemonthlaterhadhysterectomyforpoorly-
diﬀerentiated endometrioid endometrial carcinoma. After
hysterectomy, a brain magnetic resonance imaging (MRI)
demonstrated multiple brain metastases, and the patient
had two rounds of SRS and six courses of chemotherapy.
Complete response of the brain lesions was obtained, and
the patient was well without recurrence 38 months after
the second SRS [44]. Monaco et al. [53] evaluated in 2008
the outcomes after SRS for brain metastases in 6 patients
with endometrial carcinoma and 21 patients with ovarian
carcinoma. Of the 27 patients (results were not stratiﬁed
according to type of primary tumor), one patient was
still alive at the time of last followup, and 26 had died.
The median survival was 7 months after the diagnosis of
brain metastases and 5 months after SRS. Interestingly, on
ﬁnal imaging studies, all tumors were controlled without
further growth; nevertheless, 2 patients (7.4%) developed
new or progressive neurologic deﬁcits after SRS. The authors
[53] concluded that SRS provides local tumor control with
limited morbidity and is an acceptable choice for the
treatment of brain metastases resulting from endometrial
and ovarian carcinoma; however, careful patient selection
is needed in patients with uncontrolled systemic disease in
whom a limited survival beneﬁt is expected.
Although the experience of using SRS in the treatment of
brain metastases from endometrial carcinoma is still limited,
it seems that SRS will gain more popularity in the future
since patients with a limited number of brain metastases
may be treated with SRS without WBRT. Repeat SRS may
be performed for new lesions in the brain to avoid or delay
use of WBRT for as long as possible. The rationale for this
approach is the avoidance of signiﬁcant neurotoxicity from
WBRT. Patients treated with SRS alone may experience fewer
cognitive and constitutional side eﬀects. In addition, there is
an advantage for the use of SRS in treating patients with sin-
gle brain metastases who are unable to tolerate surgery and
for those with surgically inaccessible lesions. Thus, it seems
thattheroleofSRSinthetreatmentofbrainmetastasesfrom
endometrial carcinoma is expected to increase.
9.SurvivalafterDiagnosisof Brain Metastases
from Endometrial Carcinoma
The median survival after diagnosis of brain metastases of 10
patients with brain metastases from endometrial carcinoma
reported by Cormio et al. [36] was 1 month (range, 1–
83 months). The median survival after diagnosis of brain
metastases of 10 patients reported by Mahmoud-Ahmed et
al. [41] was 3.25 months (range, 0.25–15.5 months). The 8
patients with brain metastases reported by Gien et al. [46]
survived after diagnosis of brain metastases for a median of
3.5 months (range, 0.25–7 months). The median survival
after diagnosis of brain metastases of 20 patients reported by
Chura et al. [51] was 2 months (range, 0.1–39.2 months).
The 27 patients (6 endometrial carcinoma patients and 21
ovarian carcinoma patients) reported by Monaco et al. [53]
survived from the time of treatment of brain metastases with
SRS for a median of 5 months (range, 0.2–25 months).
The survival time after diagnosis of brain metastases
from endometrial carcinoma was available in 91 of 115
patients documented in the literature and ranged from 0.1
to 171 months with a median of 5 months (Table 1). In 40
patients in whom metastasis was conﬁned to the brain only
(isolated brain metastases) and survival time was available,
the median survival after diagnosis of brain metastases was
12.75 months (range, 0.25–171 months). In 44 patients in
whom brain metastasis was part of a disseminated disease
and survival time was available, the median survival after
diagnosis of brain metastases was 2.22 months (range, 0.1–
37 months). In 40 patients who had single brain metastases
andinwhomsurvivaltimewasavailable,themediansurvival
after diagnosis of brain metastases was 12.75 months (range,
0.5–171 months). In 25 patients who had multiple brain
metastases and in whom survival time was available, the
median survival after diagnosis of brain metastases was
2.5 months (range, 0.25–64 months). In 45 patients with
supratentorial (cerebral) metastases and in whom survival
time was available, the median survival after diagnosis of
brain metastases was 7 months (range, 0.25–171 months).
In 10 patients with infratentorial (cerebellar) metastases and
in whom survival time was available, the median survival
after diagnosis of brain metastases was 5.75 months (range,
1–17 months). In 8 patients with both supratentorial and
infratentorial metastases and in whom survival time was
available, the median survival after diagnosis of brain metas-
tases was 2.5 months (range, 1–8 months). In 28 patientsISRN Oncology 11
who had for their brain metastases multimodal therapy
including surgery followed by WBRT and in whom survival
time was available, the median survival after diagnosis of
brain metastases was 22 months (range, 2.1–84 months). In
8 patients who had surgery alone for their brain metastases
andinwhomsurvivaltimewasavailable,themediansurvival
after diagnosis of brain metastases was 2.25 months (range,
1–18 months). In 26 patients who had WBRT alone for their
brain metastases and in whom survival time was available,
the median survival after diagnosis of brain metastases was 2
months (range, 0.25–17 months).
Thus, generally, the survival of patients after diagnosis
of brain metastases from endometrial carcinoma is poor.
Nevertheless, the survival after diagnosis of brain metastases
is aﬀected by the status (controlled versus uncontrolled) and
extent (cranial metastases only versus cranial and extracra-
nial metastases) of the primary disease and by the number,
volume, and site of metastases in the brain parenchyma.
A relatively longer survival is achieved with multimodal
therapyincluding craniotomy (orSRS)followedbyWBRT ±
chemotherapy than by WBRT alone.
10. Conclusion
Brain metastasis from endometrial carcinoma is rare with
approximately 100 cases documented in the literature. The
incidence of brain metastases among patients with endome-
trial carcinoma is 0.6%. In 0.7% of patients with brain
metastases,thesourceofbrainmetastasesisendometrialcar-
cinoma. The primary endometrial carcinoma metastasizing
to the brain is usually an advanced-stage (III/IV) and high-
grade(G3)endometrialcarcinomathatwastreatedprimarily
by total abdominal hysterectomy and bilateral salpingo-
oophorectomy followed by adjuvant pelvic radiotherapy.
In the vast majority of patients (∼90%), brain metas-
tases are detected after diagnosis of endometrial carcinoma
(“metachronous metastases”) with a median interval from
diagnosis of endometrial carcinoma to diagnosis of brain
metastasesof 17 months. In some patients (∼10%), however,
brain metastases are diagnosed at the time of diagno-
sis of endometrial carcinoma (“synchronous metastases”)
or before the diagnosis of endometrial carcinoma. Thus,
although brain metastasis from endometrial carcinoma is
usually considered a late event in the course of the pri-
mary disease, poorly-diﬀerentiated endometrial carcinomas
with lymph-vascular and deep myometrial invasion may
metastasize early in the course of the disease, even before
clinical symptoms of the primary tumor become apparent.
Brain metastasis from endometrial carcinoma is either an
isolated disease limited to the brain only (∼50% of the
patients) or part of a disseminated disease with metastases
occurring also in other sites of the body (∼50% of the
patients). Most often, brain metastasis from endometrial
carcinoma is located in the cerebrum (75% of the patients)
and is solitary (single brain metastases) (60% of the
patients). The following variables aﬀect the prognosis and
guide treatment decisions in patients with brain metastases
from endometrial carcinoma: age and performance status
of the patient, state of control of the primary disease,
absence or presence of extracranial metastases, the number,
location, and volume of brain metastases, and mode of
therapy of brain metastases. Treatment of brain metastasis
has evolved over the years from WBRT only for most
patients to multimodal therapy including surgical resection,
if feasible, followed by WBRT and/or chemotherapy. The
median survival after diagnosis of brain metastases from
endometrial carcinoma is 5 months overall; nevertheless, a
better median survival is achieved with multimodal therapy
including craniotomy followed by WBRT (22 months)
compared to craniotomy alone (2.25 months) or WBRT
alone (2 months). The experience of using SRS in the
treatment of brain metastases from endometrial carcinoma
is still limited. Early detection of brain metastases in
endometrial carcinoma patients is of utmost importance
since brain metastases at their early stage of development
in the brain parenchyma are still of small volume and,
thus, much more feasible for surgical resection or SRS
with less complications and better survival than metastases
at advanced stage of their development. The emergence
of one of more neurological symptoms and signs in an
endometrial carcinoma patient should incite an immediate
search for brain metastases with the use of brain-imaging
studies. Moreover, it is suggested that brain-imaging studies
should be considered in the routine followup of patients
with primary endometrial carcinoma. It is also suggested
that the search for a primary source in females with brain
metastases of unknown primary should include endometrial
biopsy.
Conﬂict of Interests
The authors declare that there is no conﬂict of interests.
References
[ 1 ]R .R .L a n g l e ya n dI .J .F i d l e r ,“ T h es e e da n ds o i lh y p o t h e s i s
revisited—the role of tumor-stroma interactions in metastasis
to diﬀerent organs,” International Journal of Cancer, vol. 128,
no. 11, pp. 2527–2535, 2011.
[2] P. W. Sperduto, B. Berkey, L. E. Gaspar, M. Mehta, and W.
Curran, “A new prognostic index and comparison to three
other indices for patients with brain metastases: an analysis of
1,960 patients in the RTOG database,” International Journal of
RadiationOncologyBiologyPhysics,vol.70,no.2,pp.510–514,
2008.
[3] A. Tosoni, M. Ermani, and A. A. Brandes, “The pathogenesis
and treatment of brain metastases: a comprehensive review,”
Critical Reviews in Oncology/Hematology, vol. 52, no. 3, pp.
199–215, 2004.
[4] I. J. Fidler, “The role of the organ microenvironment in brain
metastasis,”SeminarsinCancerBiology,vol.21,no.2,pp.107–
112, 2011.
[ 5 ]L .J .S c h o u t e n ,J .R u t t e n ,H .A .M .H u v e n e e r s ,a n dA .
Twijnstra, “Incidence of brain metastases in a cohort of
patients with carcinoma of the breast, colon, kidney, and lung
and melanoma,” Cancer, vol. 94, no. 10, pp. 2698–2705, 2002.
[6] K. Ogawa, Y. Yoshii, Y. Aoki et al., “Treatment and prognosis
of brain metastases from gynecological cancers,” Neurologia
Medico-Chirurgica, vol. 48, no. 2, pp. 57–62, 2008.12 ISRN Oncology
[7] A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics,
2010,”CA:CancerJournalforClinicians,vol.60,no.5,pp.277–
300, 2010.
[8] NationalCancerInstitute,SurveillanceEpidemiologyandEnd
Results [SEER], http://seer.cancer.gov/csr/1975 2007/browse
csr.php.
[9] CancerStats—Cancer Statistics for the UK: Cancer Research
UK. Updated 3 November 2011, http://info.cancerresearchuk
.org/cancerstats/.
[10] M. Duncan, V. Seagroatt, and M. Goldacre, “Cancer of
the body of the uterus: trends in mortality and incidence
in England, 1985–2008,” British Journal of Obstetrics and
Gynaecology, vol. 119, no. 3, pp. 333–339, 2012.
[11] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D.
M. Parkin, “Estimates of worldwide burden of cancer in 2008:
GLOBOCAN 2008,” International Journal of Cancer, vol. 127,
no. 12, pp. 2893–2917, 2010.
[ 1 2 ]A .J e m a l ,F .B r a y ,M .M .C e n t e r ,J .F e r l a y ,E .W a r d ,a n dD .
Forman, “Global cancer statistics,” CA: Cancer Journal for
Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[13] N. K. Lee, “Adjuvant treatment of advanced-stage endometrial
cancer,” Clinical Obstetrics and Gynecology,v o l .5 4 ,n o .2 ,p p .
256–265, 2011.
[14] R. E. Bristow, A. Santillan, M. L. Zahurak, G. J. Gardner, R. L.
Giuntoli,andD.K.Armstrong,“Salvagecytoreductivesurgery
for recurrent endometrial cancer,” Gynecologic Oncology, vol.
103, no. 1, pp. 281–287, 2006.
[ 1 5 ]C .S .A w t r e y ,M .G .C a d u n g o g ,M .M .L e i t a oe ta l . ,“ S u r g i c a l
resection of recurrent endometrial carcinoma,” Gynecologic
Oncology, vol. 102, no. 3, pp. 480–488, 2006.
[16] S. A. Sohaib, S. L. Houghton, R. Meroni, A. G. Rockall,
P. Blake, and R. H. Reznek, “Recurrent endometrial cancer:
patterns of recurrent disease and assessment of prognosis,”
Clinical Radiology, vol. 62, no. 1, pp. 28–34, 2007.
[17] T. Evans, O. Sany, P. Pearmain, R. Ganesan, A. Blann, and
S. Sundar, “Diﬀerential trends in the rising incidence of
endometrial cancer by type: data from a UK population-based
registry from 1994 to 2006,” British Journal of Cancer, vol. 104,
no. 9, pp. 1505–1510, 2011.
[18] L. M. Duong, R. J. Wilson, U. A. Ajani, S. D. Singh, and C. R.
Eheman, “Trends in endometrial cancer incidence rates in the
United States, 1999–2006,” Journal of Women’s Health, vol. 20,
no. 8, pp. 1157–1163, 2011.
[19] K. K. Nakano and W. C. Schoene, “Endometrial carcinoma
with a predominant clear cell pattern with metastases to the
adrenal, posterior mediastinum, and brain,” American Journal
of Obstetrics & Gynecology, vol. 122, no. 4, pp. 529–530, 1975.
[20] E. Henriksen, “The lymphatic dissemination in endometrial
carcinoma: a study of 188 necropsies,” American Journal of
Obstetrics & Gynecology, vol. 123, no. 6, pp. 570–576, 1975.
[21] C. Brezinka, F. Fend, O. Huter, and A. Plattner, “Cerebral
metastasis of endometrial carcinoma,” Gynecologic Oncology,
vol. 38, no. 2, pp. 278–281, 1990.
[22] S. Paget, “The distribution of secondary growths in cancer of
the breast,” The Lancet, vol. 133, no. 3421, pp. 571–573, 1889.
[23] G. L. Nicolson and J. L. Winkelhake, “Organ speciﬁcity of
blood borne tumour metastasis determined by cell adhesion?”
Nature, vol. 255, no. 5505, pp. 230–232, 1975.
[24] J. G. Aalders, V. Abeler, and P. Kolstad, “Recurrent adenocar-
cinoma of the endometrium: a clinical and histopathological
study of 379patients,” Gynecologic Oncology, vol. 17, no. 1, pp.
85–103, 1984.
[25] B. S. Salibi and E. Beltaos, “Endometrial adenocarcinoma
with cerebral metastasis and subdural ossiﬁcation,” Wisconsin
Medical Journal, vol. 71, no. 12, pp. 255–258, 1972.
[26] D. M. Turner and C. J. Graf, “Nontraumatic subdural
hematoma secondary to dural metastasis: case report and
review of the literature,” Neurosurgery, vol. 11, no. 5, pp. 678–
680, 1982.
[ 2 7 ]W .W .R i t c h i e ,J .M .M e s s m e r ,D .P .W h i t l e y ,a n dD .R .
Gopelrud, “Uterine carcinoma metastatic to the larynx,”
Laryngoscope, vol. 95, no. 1, pp. 97–98, 1985.
[28] J. Savage, W. Subby, and T. Okagaki, “Adenocarcinoma
of the endometrium with trophoblastic diﬀerentiation and
metastases as choriocarcinoma: a case report,” Gynecologic
Oncology, vol. 26, no. 2, pp. 257–262, 1987.
[29] M. Sawada, M. Inagaki, M. Ozaki et al., “Long-term survival
after brain metastasis from endometrial cancer,” Japanese
Journal of Clinical Oncology, vol. 20, no. 3, pp. 312–315, 1990.
[30] K. Kottke-Marchant, M. L. Estes, and C. Nunez, “Early brain
metastases in endometrial carcinoma,” Gynecologic Oncology,
vol. 41, no. 1, pp. 67–73, 1991.
[31] P. M. Z. R. De Porre and A. J. S. Tjokrowardojo, “Brain
metastases of endometrial carcinoma. Case report and review
of literature,” Strahlentherapie und Onkologie, vol. 168, no. 2,
pp. 100–101, 1992.
[32] H. Thomas and H. E. Lambert, “Solitary cerebral metastases
from gynaecological malignancy: the case for radical therapy,”
Clinical Oncology, vol. 4, no. 2, pp. 133–134, 1992.
[33] M. Wronski, M. Zakowski, E. Arbit, W. J. Hoskins, and J. H.
Galicich, “Endometrial cancer metastasis to brain: report of
two cases and a review of the literature,” Surgical Neurology,
vol. 39, no. 5, pp. 355–359, 1993.
[34] A. Ruelle, M. Zuccarello, and G. Andrioli, “Brain metastasis
from endometrial carcinoma. Report of two cases,” Neurosur-
gical Review, vol. 17, no. 1, pp. 83–87, 1994.
[35] O. De Witte, F. Lefranc, I. Salmon, P. Violon, and J. Brotchi,
“Brain metastasis from gynecological cancer,” Neurochirurgie,
vol. 42, no. 4-5, pp. 216–220, 1996.
[36] G. Cormio, A. Lissoni, G. Losa, G. Zanetta, A. Pellegrino, and
C.Mangioni,“Brainmetastasesfromendometrialcarcinoma,”
Gynecologic Oncology, vol. 61, no. 1, pp. 40–43, 1996.
[37] M. Salvati, L. Cervoni, and M. Raguso, “Therapeutic obser-
vations of solitary cerebral metastases due to endometrial
carcinoma,” Minerva Ginecologica, vol. 50, no. 10, pp. 445–
447, 1998.
[38] R. M. Mart´ ınez-Ma˜ nas, M. Brell, J. Rumi` a, and E. Ferrer,
“Brain metastases in endometrial carcinoma,” Gynecologic
Oncology, vol. 70, no. 2, pp. 282–284, 1998.
[39] K. Ogawa, T. Toita, Y. Kakinohana et al., “Palliative radiation
therapy for brain metastases from endometrial carcinoma:
report of two cases,” Japanese Journal of Clinical Oncology, vol.
29, no. 10, pp. 498–503, 1999.
[40] M. Crispino, A. Tira, D. Volpi, and L. Olivetti, “Solitary
cerebral metastasis of endometrial carcinoma,” La Radiologia
Medica, vol. 100, no. 6, pp. 515–517, 2000.
[41] A. S. Mahmoud-Ahmed, J. H. Suh, G. H. Barnett, K. D.
Webster, J. L. Belinson, and A. W. Kennedy, “The eﬀect
of radiation therapy on brain metastases from endometrial
carcinoma: a retrospective study,” Gynecologic Oncology, vol.
83, no. 2, pp. 305–309, 2001.
[42] E. Petru, S. Lax, S. Kurschel, F. G¨ ucer, and B. Sutter, “Long-
term survival in a patient with brain metastases preceding
the diagnosis of endometrial cancer: report of two cases and
review of the literature,” Journal of Neurosurgery, vol. 94, no. 5,
pp. 846–848, 2001.ISRN Oncology 13
[43] S. Sewak, F. M. Muggia, and D. Zagzag, “Endometrial
carcinoma with cerebellar metastasis: a case report and review
of the literature,” Journal of Neuro-Oncology,v o l .5 8 ,n o .2 ,p p .
137–140, 2002.
[44] S. Shiohara, M. Ohara, K. Itoh, T. Shiozawa, and I. Konishi,
“Successful treatment with stereotactic radiosurgery for brain
metastasesofendometrialcarcinoma:acasereportandreview
oftheliterature,”InternationalJournalofGynecologicalCancer,
vol. 13, no. 1, pp. 71–76, 2003.
[45] K.S.Elliott,M.E.Borowsky,Y.C.Lee,C.Rao,andO.Abulaﬁa,
“Prolonged survival in recurrent endometrial carcinoma to
the brain,” Gynecologic Oncology, vol. 95, no. 1, pp. 247–251,
2004.
[46] L. T. Gien, J. S. Kwon, D. P. D’Souza et al., “Brain metastases
from endometrial carcinoma: a retrospective study,” Gyneco-
logic Oncology, vol. 93, no. 2, pp. 524–528, 2004.
[47] M. Salvati, E. Caroli, E. R. Orlando et al., “Solitary brain
metastases from uterus carcinoma: report of three cases,”
Journal of Neuro-Oncology, vol. 66, no. 1-2, pp. 175–178, 2004.
[48] W. J. Lee, C. H. Chen, and S. N. Chow, “Brain metastases
from early stage endometrial carcinoma 8years after primary
treatment: case report and review of the literature,” Acta
Obstetricia et Gynecologica Scandinavica, vol. 85, no. 7, pp.
890–891, 2006.
[49] A. P. Llaneza-Coto, M. Seco-Navedo, T. Fern´ andez-Garc´ ıa,
and M. Redondo-Onia, “Brain metastases of endometrial
carcinoma in a young woman,” Progresos de Obstetricia y
Ginecologia, vol. 49, no. 2, pp. 82–84, 2006.
[50] S. Orr` u, G. Lay, M. Dess` ı, R. Murtas, M. A. Deidda, and M.
Amichetti, “Brain metastases from endometrial carcinoma:
report of three cases and review of the literature,” Tumori, vol.
93, no. 1, pp. 112–117, 2007.
[51] J. C. Chura, R. Marushin, A. Boyd, R. Ghebre, M. A.
Geller, and P. A. Argenta, “Multimodal therapy improves
survival in patients with CNS metastasis from uterine cancer:
a retrospective analysis and literature review,” Gynecologic
Oncology, vol. 107, no. 1, pp. 79–85, 2007.
[52] C.Ramirez,N.Reyns,D.Pasquier,andS.Blond,“Bilateraltha-
lamic metastases in endometrial adenocarcinoma,” European
Neurology, vol. 59, no. 6, p. 330, 2008.
[53] E. Monaco, D. Kondziolka, S. Mongia, A. Niranjan, J.
C. Flickinger, and L. D. Lunsford, “Management of brain
metastases from ovarian and endometrial carcinoma with
stereotactic radiosurgery,” Cancer, vol. 113, no. 9, pp. 2610–
2614, 2008.
[54] A. Al-Mujaini, M. Gans, and J. Deschˆ enes, “Cortical visual
loss consequent to brain metastases from an endometrial
carcinoma,” Canadian Journal of Ophthalmology, vol. 43, no.
4, p. 486, 2008.
[55] M. D. Forster, K. J. Dedes, S. Sandhu et al., “Treatment
with olaparib in a patient with PTEN-deﬁcient endometrioid
endometrial cancer,” Nature Reviews Clinical Oncology, vol. 8,
no. 5, pp. 302–306, 2011.
[56] T. Berge and S. Lundberg, “Cancer in Malmo 1958–1969. An
autopsystudy,”ActaPathologicaetMicrobiologicaScandinavica
A, vol. 85, supplement 260, 235 pages, 1977.
[57] K. Kishi, K. Nomura, Y. Miki, S. Shibui, and K. Takakura,
“Metastatic brain tumor. A clinical and pathologic analysis of
101 cases with biopsy,” Archives of Pathology and Laboratory
Medicine, vol. 106, no. 3, pp. 133–135, 1982.
[58] A. H. Graf, W. Buchberger, H. Langmayr, and K. W. Schmid,
“Site preference of metastatic tumours of the brain,” Virchows
Archiv A, vol. 412, no. 5, pp. 493–498, 1988.
[59] T. Le Chevalier, F. P. Smith, P. Caille, J. P. Constans, and J. G.
Rouesse, “Sites of primary malignancies in patients presenting
with cerebral metastases: a review of 120 cases,” Cancer, vol.
56, no. 4, pp. 880–882, 1985.
[60] J. Y. Delattre, G. Krol, H. T. Thaler, and J. B. Posner,
“Distribution of brain metastases,” Archives of Neurology, vol.
45, no. 7, pp. 741–744, 1988.